Similar companies
Income Statement (USD)
Q1 '25 | QoQ | |
---|---|---|
Operating expense | 222M | 16.7% |
Net Income | -222M | 18.6% |
EBITDA | -222M | 18.2% |
Balance Sheet (USD)
Q1 '25 | QoQ | |
---|---|---|
Total Assets | 459M | 25.4% |
Total Liabilities | 199M | 4.1% |
Total Equity | 259M | 38.7% |
Shares Outstanding | 102M | 0.9% |
Cash Flow (USD)
Q1 '25 | QoQ | |
---|---|---|
Cash from operations | -165M | 3.3% |
Cash from financing | 370,000 | 99.9% |
EPS
Financial Highlights for Biohaven in Q1 '25
Operating Expenses for this period were 222M, showing a 16.7% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -222M, showing a -18.6% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -222M, showing a -18.2% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Biohaven faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.